Related Experiment Video

Updated: Aug 14, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

[Experimental therapy of survivin antisense oligonucleotide for human ovarian cancer cell SKOV3]

Shu-Qin Wei1, Sheng Bi, Jian-Hua Zheng

  • 1Department of Obstetrics & Gynecology, The First Clinical College, Harbin Medical University, Harbin, Heilongjiang, 150001, PR China. weishuqin@hotmail.com

AI Zheng = Aizheng = Chinese Journal of Cancer
|August 11, 2004
PubMed
Abstract

Insights

Survivin antisense oligonucleotide (ASODN) effectively inhibits human ovarian cancer cell growth by reducing survivin expression and inducing apoptosis. This suggests ASODN is a promising anti-cancer therapeutic for ovarian carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Survivin is overexpressed in various human tumors, potentially driving tumor development.
  • Targeting survivin offers a potential strategy for cancer therapy.

Purpose of the Study:

  • To investigate the inhibitory effects of survivin antisense oligonucleotide (ASODN) on human ovarian carcinoma SKOV3 cells.
  • To elucidate the mechanism of ASODN-mediated inhibition in ovarian cancer.

Main Methods:

  • SKOV3 cells were transfected with survivin ASODN using DOTAP liposomes.
  • Cell proliferation was assessed by MTT assay; gene expression by Western blot.
  • Apoptosis was analyzed using flow cytometry, DNA laddering, and DAPI staining; caspase-3 activity was measured.

Main Results:

  • Survivin expression was significantly reduced in SKOV3 cells post-ASODN transfection.
  • ASODN transfection inhibited SKOV3 cell proliferation, with a 1000 ng/ml dose yielding a 60.30% inhibition rate.
  • ASODN induced G1 cell cycle arrest, increased apoptosis from 0.65% to 32.10%, and significantly elevated caspase-3 activity.

Conclusions:

  • Survivin ASODN effectively inhibits human ovarian carcinoma SKOV3 cell proliferation.
  • ASODN induces apoptosis in ovarian cancer cells, indicating a potential anti-cancer mechanism.
  • Survivin ASODN represents a prospective therapeutic agent for ovarian cancer treatment.

More Related Videos

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

Evaluation of Stem Cell Properties in Human Ovarian Carcinoma Cells Using Multi and Single Cell-based Spheres Assays08:39

Evaluation of Stem Cell Properties in Human Ovarian Carcinoma Cells Using Multi and Single Cell-based Spheres Assays

Published on: January 3, 2015

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...